Neogen Chemicals Q2 FY26: Profit Plunges 69% as Interest Costs Surge

The quarter's performance represents a continuation of deteriorating trends for the Thane-based chemical manufacturer. On a sequential basis, consolidated profit collapsed 67.15% from ₹10.26 crores in Q1 FY26, despite revenue growing 11.74% quarter-on-quarter to ₹208.66 crores. The company's profitability metrics have contracted across the board, with PAT margin shrinking to a mere 1.62% from 5.67% a year ago, whilst operating margin excluding other income declined to 14.36% from 17.85% in Q2 FY25.

The financial carnage was primarily driven by a 52.78% year-on-year surge in interest expenses, which ballooned to ₹19.48 crores—the highest quarterly interest burden in the company's recent history. This dramatic increase in borrowing costs reflects the company's aggressive capacity expansion programme, with long-term debt rising to ₹170.10 crores as of March 2025 from ₹124.23 crores a year earlier. The interest coverage ratio, measured by operating profit to interest, plummeted to a concerning 1.54 times in Q2 FY26, down from 2.70 times in the year-ago period.

Financial Performance: Margin Compression Amidst Volume Growth

Whilst Neogen Chemicals achieved its highest-ever quarterly revenue of ₹208.66 crores in Q2 FY26, the top-line growth failed to translate into bottom-line expansion. The 7.91% year-on-year revenue increase was accompanied by a disproportionate 63.75% surge in employee costs to ₹24.29 crores, suggesting aggressive hiring or wage inflation. Operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI) declined to ₹29.96 crores, marking the lowest level in recent quarters despite peak revenue.

The company's gross profit margin deteriorated sharply to 5.93% in Q2 FY26 from 11.66% in the year-ago period, indicating either pricing pressure in the specialty chemicals market or elevated raw material costs. This margin compression was partially offset by a reduction in the tax rate to 34.56% from 29.20% year-on-year, though this provided little solace given the weak pre-tax profitability. Profit before tax stood at a mere ₹5.15 crores, down 66.73% year-on-year, whilst other income contributed ₹1.89 crores, representing 36.70% of profit before tax—a concerning indicator of weak operational profitability.

On a half-yearly basis (H1 FY26), the picture remains challenging. Consolidated net profit for the six months ended September 2025 stood at ₹13.63 crores, down 39.30% from ₹22.43 crores in H1 FY25, whilst revenue grew 6.00% to ₹395.39 crores. The persistent margin pressure and elevated interest burden have resulted in a negative financial trend classification, with the company's quarterly PAT falling 68.5% versus the previous four-quarter average.

Operational Challenges: The Interest Burden and Leverage Concerns

The most glaring operational challenge facing Neogen Chemicals is its deteriorating debt serviceability. The company's interest coverage ratio has collapsed to 1.54 times in Q2 FY26, down from 2.77 times in Q2 FY24, raising questions about financial sustainability. With operating profit before interest and tax (EBIT) barely covering interest expenses, the company has minimal cushion to absorb further operational setbacks or interest rate increases.

The balance sheet reveals a company under financial strain. Total borrowings (long-term and short-term) have increased substantially, with long-term debt at ₹170.10 crores as of March 2025. The debt-to-EBITDA ratio averaged 3.39 times over recent periods, whilst net debt-to-equity stood at 0.75 times—both metrics indicating moderate to elevated leverage for a company in a cyclical industry. Current liabilities surged to ₹733.40 crores in FY25 from ₹526.98 crores in FY24, driven by a near-doubling of trade payables to ₹263.19 crores, suggesting potential working capital pressures.

The company's capacity expansion programme, whilst strategically necessary for long-term growth, has front-loaded costs without commensurate revenue benefits. Fixed assets declined to ₹374.58 crores in FY25 from ₹481.52 crores in FY24, suggesting either asset disposals or aggressive depreciation. Meanwhile, cash flow from operations turned positive at ₹195.00 crores in FY25 after two consecutive years of negative operating cash flows, though this was more than offset by ₹316.00 crores in investing activities, necessitating ₹113.00 crores in financing inflows.

Industry Context: Specialty Chemicals Under Pressure

Neogen Chemicals' struggles mirror broader challenges in the Indian specialty chemicals sector, which has faced headwinds from Chinese competition, pricing pressure, and demand softness in key export markets. The company's 7.91% revenue growth in Q2 FY26, whilst positive, lags the robust 19.77% five-year sales CAGR, suggesting a deceleration in growth momentum. The operating margin contraction to 14.36% from historical levels above 17% indicates either competitive intensity or input cost inflation that cannot be passed through to customers.

The specialty chemicals industry has witnessed inventory corrections and demand normalisation following the post-pandemic boom, with many players reporting margin pressures. Neogen's product portfolio—focused on bromine-based compounds, lithium salts, and Grignard reagents—serves pharmaceuticals, agrochemicals, and advanced materials sectors, which have exhibited mixed demand patterns. The company's inability to sustain margins despite revenue growth suggests limited pricing power, a concerning indicator in a business that requires continuous capital investment.

Neogen Chemicals trades at a significant valuation premium to peers despite delivering inferior returns. At 89.78 times trailing twelve-month earnings, the stock commands a P/E multiple nearly double the peer average of approximately 43 times. More concerningly, the company's ROE of 9.58% trails the peer average of roughly 15%, whilst its price-to-book ratio of 4.87 times exceeds the peer average of 3.7 times. This valuation-quality mismatch suggests the market has yet to fully digest the company's deteriorating fundamentals, presenting significant downside risk.

Valuation Analysis: Premium Unjustified by Fundamentals

Neogen Chemicals' current valuation metrics paint a picture of a stock trading at stratospheric multiples disconnected from underlying business performance. At a P/E ratio of 89.78 times, the stock trades at more than double the specialty chemicals industry average P/E of 42 times, despite delivering weak profitability growth. The price-to-book ratio of 4.87 times appears particularly stretched given the company's ROE of just 5.58% in the latest period—well below the cost of equity for a small-cap chemical manufacturer.

The company's EV/EBITDA multiple of 32.40 times and EV/EBIT multiple of 40.26 times rank amongst the highest in the specialty chemicals peer group, despite operating margins contracting and interest coverage deteriorating. The PEG ratio of 6.12 indicates the stock is expensive relative to its growth prospects, with the market pricing in aggressive earnings recovery that current trends do not support. At the current market price of ₹1,458.55, the stock has declined 39.60% from its 52-week high of ₹2,414.90, yet remains 4.54% above its 52-week low of ₹1,395.25, suggesting limited downside cushion.

The valuation grade has been classified as "Very Expensive" since early 2020, with the stock oscillating between "Very Expensive" and "Risky" categories. Given the recent profit collapse and margin compression, a fair value estimate would require significant downward revision. Based on peer multiples and the company's deteriorating return profile, a fair P/E ratio of 30-35 times appears more appropriate, implying a fair value range of ₹500-580 per share—representing 60-62% downside from current levels. The dividend yield of 0.07% provides negligible income support, whilst the payout ratio of 14.80% suggests the company is conserving cash amidst financial strain.

Shareholding Pattern: Institutional Confidence Wavering

The shareholding pattern reveals shifting institutional sentiment towards Neogen Chemicals. Promoter holding has remained stable at 51.23% over the past five quarters, with no pledging of shares—a positive indicator of promoter confidence and financial stability at the ownership level. However, institutional investor behaviour tells a more nuanced story.

Foreign Institutional Investors (FIIs) have been consistent sellers, reducing their stake from 8.17% in September 2024 to 5.15% in September 2025—a decline of 302 basis points over the year. The sequential quarter saw a sharp 221 basis point reduction from 7.36% to 5.15%, suggesting accelerated foreign selling following the weak Q2 results. This exodus of foreign capital reflects growing concerns about the company's profitability trajectory and valuation sustainability.

Conversely, domestic mutual funds have increased their stake from 19.96% to 22.76% over the same period, with a notable 234 basis point increase in Q2 FY26 alone. This divergence between foreign and domestic institutional behaviour is intriguing—either domestic funds see contrarian value that foreign investors do not, or they are providing liquidity support to a falling stock. Insurance companies have marginally increased their holding to 1.75%, whilst other domestic institutional investors have reduced their stake to 0.71%. Overall institutional holding stands at 30.38%, with 62 FIIs and 15 mutual funds holding positions.

Stock Performance: Severe Underperformance Across Timeframes

Neogen Chemicals' stock performance has been dismal across virtually all timeframes, significantly underperforming both the Sensex and its specialty chemicals peer group. The stock has generated negative alpha across most periods, indicating consistent value destruction relative to the broader market.

The stock's year-to-date decline of 33.96% contrasts sharply with the Sensex's 6.50% gain, resulting in negative alpha of 40.46 percentage points. Over the past year, the stock has underperformed the Sensex by 39.14 percentage points, whilst the three-year underperformance stands at 32.85 percentage points. The only bright spot is the five-year return of 120.39%, which outperformed the Sensex's 98.64% gain by 21.75 percentage points, though this reflects the stock's strong performance during the 2020-2022 period rather than recent trends.

The stock's risk-adjusted return of -0.74 over the past year, combined with volatility of 46.52%, places it in the "high risk, low return" category—an unattractive risk-reward profile for investors. The stock's beta of 1.35 indicates it is 35% more volatile than the market, amplifying losses during downturns without corresponding upside capture during rallies. Technical indicators paint a uniformly bearish picture, with the stock trading below all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), whilst the overall technical trend is classified as "mildly bearish."

Investment Thesis: Multiple Red Flags Outweigh Limited Positives

The investment thesis for Neogen Chemicals has deteriorated markedly, with the company's proprietary Mojo Score plunging to 24 out of 100—firmly in "Strong Sell" territory. The score reflects a confluence of negative factors: deteriorating financial trends, bearish technical indicators, stretched valuation, and declining quality metrics. The company's quality grade has been downgraded to "Average" from "Good," reflecting the sustained erosion in return ratios and profitability metrics.

The near-term drivers are unambiguously negative, with quarterly financial trends classified as negative and technical indicators pointing to continued weakness. The company's operating profit-to-interest coverage has fallen to its lowest level at 1.54 times, whilst operating margin has compressed to 14.36%—the lowest in recent quarters despite record revenue. The quality assessment reveals poor long-term growth in operating profit (15.27% CAGR over five years), weak average ROCE of 12.50%, and weak average ROE of 9.58%.

Key Strengths and Risk Factors

Outlook: What to Monitor

The forward outlook for Neogen Chemicals remains challenging. The company must demonstrate its ability to translate revenue growth into bottom-line expansion, which requires either significant margin recovery or substantial debt reduction to lower interest costs. The capacity expansions undertaken in recent years need to generate returns that justify the capital deployed, which is not evident in current financial performance. Until the company can sustainably generate ROE and ROCE above its cost of capital whilst reducing leverage, the investment case remains weak.

Market consensus expectations, if any, appear overly optimistic given current trends. The stock's valuation implies expectations of a sharp profit recovery that current operational metrics do not support. Investors should monitor Q3 FY26 results closely for signs of margin stabilisation and interest cost moderation. However, given the structural nature of the challenges—elevated debt, compressed margins, and intense competition—a sustained turnaround may require multiple quarters to materialise.